Ebola: NIH Grants License Agreement for Candidate Vaccines
NIAID today announced a license agreement aimed at advancing dual-purpose candidate vaccines to protect against rabies and Ebola viruses. The vaccines, created by scientists at NIAID and Thomas Jefferson University, have been licensed to Exxell BIO of Saint Paul, Minnesota, which aims to advance the products through clinical testing and commercialization. The vaccines are being developed to prevent rabies and Ebola infection in people and to help prevent transmission of the viruses from animals to people.
No hay comentarios:
Publicar un comentario